Literature DB >> 14692517

Clonal cytotoxic T cells in myeloma.

Daniel M Y Sze1, Ross D Brown, Edna Yuen, John Gibson, Joy Ho, Maria Raitakari, Antony Basten, Douglas E Joshua, Barbara Fazekas de St Groth.   

Abstract

Multiple myeloma (MM) is a malignant disease characterized by accumulation of morphologically recognizable plasma cells producing immunoglobulin (Ig) in the bone marrow. The occurrence of clonal T cells in MM, as defined by the presence of rearrangements in the T-cell receptor (TCR)-beta chains detected on Southern blotting, is associated with an improved prognosis. This review aims to describe the various ways in which we have demonstrated the presence of such T cell clones, and to describe the phenotype of these cells. Finally, the specificities of these clinically important CD8+ T cell populations will be discussed in the context of immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14692517     DOI: 10.1080/1042819031000097438

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  8 in total

1.  Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry.

Authors:  Roberto J Pessoa de Magalhães; María-Belén Vidriales; Bruno Paiva; Carlos Fernandez-Gimenez; Ramón García-Sanz; Maria-Victoria Mateos; Norma C Gutierrez; Quentin Lecrevisse; Juan F Blanco; Jose Hernández; Natalia de las Heras; Joaquin Martinez-Lopez; Monica Roig; Elaine Sobral Costa; Enrique M Ocio; Martin Perez-Andres; Angelo Maiolino; Marcio Nucci; Javier De La Rubia; Juan-Jose Lahuerta; Jesús F San-Miguel; Alberto Orfao
Journal:  Haematologica       Date:  2012-07-06       Impact factor: 9.941

Review 2.  Implementing liquid biopsies into clinical decision making for cancer immunotherapy.

Authors:  Dagmar Quandt; Hans Dieter Zucht; Arno Amann; Anne Wulf-Goldenberg; Carl Borrebaeck; Michael Cannarile; Diether Lambrechts; Herbert Oberacher; James Garrett; Tapan Nayak; Michael Kazinski; Charles Massie; Heidi Schwarzenbach; Michele Maio; Robert Prins; Björn Wendik; Richard Hockett; Daniel Enderle; Mikkel Noerholm; Hans Hendriks; Heinz Zwierzina; Barbara Seliger
Journal:  Oncotarget       Date:  2017-07-18

3.  Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myeloma.

Authors:  Nicholas A Gherardin; Liyen Loh; Lorenztino Admojo; Alexander J Davenport; Kelden Richardson; Amy Rogers; Phillip K Darcy; Misty R Jenkins; H Miles Prince; Simon J Harrison; Hang Quach; David P Fairlie; Katherine Kedzierska; James McCluskey; Adam P Uldrich; Paul J Neeson; David S Ritchie; Dale I Godfrey
Journal:  Sci Rep       Date:  2018-03-07       Impact factor: 4.379

4.  MED15, transforming growth factor beta 1 (TGF-β1), FcγRIII (CD16), and HNK-1 (CD57) are prognostic biomarkers of oral squamous cell carcinoma.

Authors:  Maryam Elahi; Vahid Rakhshan
Journal:  Sci Rep       Date:  2020-05-21       Impact factor: 4.379

Review 5.  Treg and Oligoclonal Expansion of Terminal Effector CD8+ T Cell as Key Players in Multiple Myeloma.

Authors:  Douglas E Joshua; Slavica Vuckovic; James Favaloro; Ka Hei Aleks Lau; Shihong Yang; Christian E Bryant; John Gibson; Phoebe Joy Ho
Journal:  Front Immunol       Date:  2021-02-23       Impact factor: 7.561

6.  Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance.

Authors:  C Bryant; H Suen; R Brown; S Yang; J Favaloro; E Aklilu; J Gibson; P J Ho; H Iland; P Fromm; N Woodland; N Nassif; D Hart; D E Joshua
Journal:  Blood Cancer J       Date:  2013-09-13       Impact factor: 11.037

Review 7.  Functional Significance of CD57 Expression on Human NK Cells and Relevance to Disease.

Authors:  Carolyn M Nielsen; Matthew J White; Martin R Goodier; Eleanor M Riley
Journal:  Front Immunol       Date:  2013-12-09       Impact factor: 7.561

Review 8.  Actors on the Scene: Immune Cells in the Myeloma Niche.

Authors:  Patrizia Leone; Antonio Giovanni Solimando; Eleonora Malerba; Rossella Fasano; Alessio Buonavoglia; Fabrizio Pappagallo; Valli De Re; Antonella Argentiero; Nicola Silvestris; Angelo Vacca; Vito Racanelli
Journal:  Front Oncol       Date:  2020-10-29       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.